Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

47.86 -2.31 (-4.60%)
Streaming Delayed Price Updated: 12:26 PM EST, Feb 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
News headline image
Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗
Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Editas Medicine Downgraded: Analyst Sees Limited Near-Term Catalysts ↗
Editas Medicine faces a downgrade to Underperform from BofA, citing competition, limited catalysts, and a reduced price target of $1 from $13. 
Via Benzinga
News headline image
Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? ↗
Via The Motley Fool
News headline image
3 Monster Stocks in the Making ↗
Via The Motley Fool
News headline image
Deciphering Disruption: Inside Cathie Wood's Latest Plays
Cathie Wood's recent stock market activity offers a glimpse into her evolving investment strategy and the potential of disruptive technologies. 
Via MarketBeat
Topics Artificial Intelligence ETFs
News headline image
Where Will CRISPR Therapeutics Be in 3 Years? ↗
Via The Motley Fool
News headline image
2 Top Biotech Stocks to Buy Now and Hold For 5 Years or More ↗
Via The Motley Fool
News headline image
3 Unstoppable Growth Stocks I'm Loading $25,000 Each Into by 2029 ↗
These three emerging technology leaders are pioneering quantum computing, gene editing, and electric aviation. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The rock star fund investor made a lot of big moves on Thursday. 
Via The Motley Fool
News headline image
Smaller Cap Biotechs Are In Season: How Are We Doing? ↗
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
News headline image
3 Companies Building Tomorrow's Game-Changing Technologies ↗
These pioneering companies are transforming delivery, medicine, and space access--potentially creating massive opportunities for early investors. 
Via The Motley Fool
News headline image
Thinking of Buying CRISPR Therapeutics Stock? Watch These 2 Key Numbers ↗
It won't be able to be profitable without hitting its targets for both of these figures. 
Via The Motley Fool
News headline image
Cathie Wood's Ark Innovation, Genomic ETFs Celebrate 10 Years: How Annual Returns Stack Up Against S&P 500 ↗
The Ark Innovation and Ark Genomic ETFs turn ten years old. A look at the annual returns and current top holdings. 
Via Benzinga
Topics ETFs Stocks
News headline image
12 High-Growth Stocks That Could Deliver Parabolic Returns ↗
These 12 innovative companies could deliver exponential returns over the next quarter century. 
Via The Motley Fool
News headline image
The Ultimate Biotech Stock to Buy With $50 Right Now ↗
This company might be worth far more than many realize. 
Via The Motley Fool
News headline image
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗
The aggressive growth icon kicked off the new trading week by buying some of her favorite stocks. 
Via The Motley Fool
News headline image
Why We Buy Stocks ↗
Is fear of missing out (FOMO) controlling your portfolio? 
Via The Motley Fool
News headline image
3 Bargain Stocks to Buy in a Market That's Priced for Perfection ↗
Yes, bargains can still be found in the stock market. 
Via The Motley Fool
News headline image
Why I Keep Buying These 14 Incredible Growth Stocks ↗
This diverse set of growth stocks offers tremendous opportunities in the fields of AI, space, biotech, and emerging industries. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Is CRISPR Therapeutics Stock a Buy? ↗
The markets this biotech is looking to enter could be extremely lucrative. 
Via The Motley Fool
News headline image
2 Biotech Stocks That Are Screaming Buys This Month ↗
They won't remain southbound forever. 
Via The Motley Fool
News headline image
This Healthcare Growth Stock Could Be a Steal of a Deal Right Now ↗
CRISPR Therapeutics is trading around multiyear lows. 
Via The Motley Fool
News headline image
These 2 Healthcare Stocks With Big Catalysts on the Horizon Can Make You Richer ↗
Market-beating returns could be on the way for patient investors in these two up-and-coming healthcare growth stocks. 
Via The Motley Fool
News headline image
Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. ↗
Pfizer stock dipped Thursday after the company voluntarily pulled its sickle cell drug, Oxbryta, from the market following patient deaths. 
Via Investor's Business Daily
News headline image
3 Dirt Cheap Stocks to Buy Right Now ↗
Bargain hunters should love these great stocks. 
Via The Motley Fool
News headline image
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy? ↗
There's a lot of growth on the way, and soon. 
Via The Motley Fool
News headline image
1 Biotech Stock Down 62% to Buy and Hold ↗
It's an excellent opportunity to buy shares of what could become a biotech giant on the dip. 
Via The Motley Fool
News headline image
3 No-Brainer Biotech Stocks to Buy With $200 Right Now ↗
An investment in these players today could score a big win down the road. 
Via The Motley Fool
News headline image
Looking for Stock Bargains With Room to Run? Try This. ↗
Investing tips from Bill Mann, The Motley Fool's director of small-cap research. 
Via The Motley Fool
News headline image
Down Nearly 50% From Its 52-Week High, Is CRISPR Therapeutics a Steal of a Deal? ↗
Is the potential upside for CRISPR Therapeutics too massive to ignore? 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
35 36 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.